BioClinica Announces Major New Release of Express EDC Solution

BioClinica Announces Major New Release of Express EDC Solution
- Interoperability with Trident IWR and OnPoint CTMS Redefines Suite - 

NEWTOWN, Pa., Sep 12, 2011 (BUSINESS WIRE) -- BioClinica(R), Inc. /quotes/zigman/113763 BIOC +0.86% , a global provider of clinical trial management solutions, announced the latest release of BioClinica Express EDC. This modern, web-based platform is a comprehensive electronic data capture (EDC) solution that adds speed and quality to every part of the clinical trial process. Enhanced to utilize the latest web technologies, Express EDC makes it easier to monitor protocol compliance and close studies faster while meeting necessary regulations and guidelines. The newest Express application improves on the usability that sites already consider 'easiest' with flexible, scalable technology that coordinates and organizes the collection and dissemination of clean data.

Express joins BioClinica's other solutions to improve the efficiency and flexibility required for modern clinical trials. Express is fully integrated in real-time with BioClinca's Trident IWR and OnPoint CTMS systems. This enables real time data exchange between Express and OnPoint CTMS to support site payment data or visit status updates. Complementing best-in-class functionality is a web services architecture that communicates in real-time between applications and maximizes data visibility and utility via SharePoint with built-in connectivity to Outlook and other Microsoft Office applications. Express also provides on-demand exports for further analysis in SAS or other analytical tools.

"This release of Express EDC is a major advancement for the BioClinica Suite. Sponsors and CROs can choose any of our world-class solutions as a stand-alone or a starting point - then augment functionality for any study when they need it," said Peter Benton, President of eClinical Solutions for BioClinica. "With the only portfolio of eClinical applications all created within the last five years, BioClinica offers a remarkably different approach with fresh ideas to address the challenges facing clinical organizations globally."

BioClinica Express provides new capabilities for EDC power users that make slicing and dicing incoming data fast and easy and automatically encodes medical terms within the same application. Role-specific dashboards focus attention where it's needed the most and data managers can tag or bookmark data to facilitate workflow, save customized data and query listings as 'private' or 'public' for later use. Study build timelines are minimized using an innovative design environment that reduces programming and maximizes re-usability.

Express delivers CDISC-compliant output at the end of the trial to save sponsors time and maximize exchange or integration with partners. Express can also incorporate external data such as labs, PK data, imaging metadata, and other instrumentation data with the clinical data during the trial. This process eliminates end-of-study reconciliation, provides cleaner data faster, and simplifies the submission process.

See BioClinica Express EDC at the 2011 SCDM (Society for Clinical Data Management) Annual Conference in Baltimore at booth #401.

Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog , and on twitter at http://twitter.com/bioclinica .

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.